title: Donating used CARs.
abstract: In this issue of Blood, Kochenderfer et al show that engineered CD19–chimeric antigen receptor (CAR) and donor-derived allogeneic T cells can safely treat CD19-positive B-cell malignancies, which have relapsed after allogeneic stem cell transplantation.
authors: UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE;
authors: Aaron P
authors: AP
authors: Rapoport
mesh_terms: D018941:Antigens, CD19; D005260:Female; D006801:Humans; D017710:Lymphocyte Transfusion; D016393:Lymphoma, B-Cell / Q000628:therapy*; D008297:Male; D011948:Receptors, Antigen, T-Cell / Q000096:biosynthesis*; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000378:metabolism* / Q000637:transplantation*
chemical_list: D018941:Antigens, CD19; D011948:Receptors, Antigen, T-Cell